News

Teva’s CEP-33237 is an investigational, 12-hour, acetaminophen-free, formulation of extended-release hydrocodone designed to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative

The approval was on based data from the EDITION clinical trial program, which included a series of international Phase III trials evaluating the efficacy and safety of Toujeo

The three-year deal will see both companies jointly develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (ROR?). According to AstraZeneca, RORy helps to convert a population of

Farydak is the first histone deacetylase (HDAC) inhibitor approved in combination with bortezomib, a type of chemotherapy, and dexamethasone, an anti-inflammatory medication, to treat patients who received at

The trial evaluated the efficacy, safety, tolerability as well as compared two active arms of different doses of TEV-48125, administered as a subcutaneous injection, once a month for

The company’s ANDA product is a generic version of Salix Pharmaceuticals’ Uceris, which is a glucocorticosteroid designed for the induction of remission in patients with active, mild to

As part of the deal, Ipsen has paid €6m for the option to acquire Canbex at the completion of a Phase IIa trial under which the latter’s present

The Phase II trial met its co-primary immunogenicity objectives regarding co-administration of Trumenba with MCV4 and Tdap vaccines. The randomized, controlled, observer-blinded Phase II trial evaluated the safety,

The Irish firm will also make additional, undisclosed, payments to Meritage based on the achievement of drug development and regulatory milestones. Shire Research and Development head Philip Vickers